JPH0491024A - Anthelminthic, insecticide and antiprotozoal - Google Patents
Anthelminthic, insecticide and antiprotozoalInfo
- Publication number
- JPH0491024A JPH0491024A JP2206479A JP20647990A JPH0491024A JP H0491024 A JPH0491024 A JP H0491024A JP 2206479 A JP2206479 A JP 2206479A JP 20647990 A JP20647990 A JP 20647990A JP H0491024 A JPH0491024 A JP H0491024A
- Authority
- JP
- Japan
- Prior art keywords
- substance
- antiprotozoal
- animals
- anthelminthic
- parasites
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002917 insecticide Substances 0.000 title claims abstract description 12
- 239000003904 antiprotozoal agent Substances 0.000 title claims abstract description 8
- 230000000507 anthelmentic effect Effects 0.000 title abstract description 13
- 230000000842 anti-protozoal effect Effects 0.000 title abstract 4
- 239000000126 substance Substances 0.000 claims abstract description 41
- 230000003115 biocidal effect Effects 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- MXPYTLCDIMCGEQ-UHFFFAOYSA-N ikd-8344 Chemical compound C1C(O2)CCC2C(C)C(=O)CC(O2)CCC2C(C)C(=O)OC(C(C)C2OC(C)CC2)CC(O2)CCC2C(C)C(=O)CC(O2)CCC2C(C)C(=O)OC1C(C)C1CCC(C)O1 MXPYTLCDIMCGEQ-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000000921 anthelmintic agent Substances 0.000 claims description 6
- 229940124339 anthelmintic agent Drugs 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 abstract description 19
- 244000045947 parasite Species 0.000 abstract description 14
- 241000238631 Hexapoda Species 0.000 abstract description 8
- 230000000749 insecticidal effect Effects 0.000 abstract description 6
- 241000238876 Acari Species 0.000 abstract description 4
- 230000000259 anti-tumor effect Effects 0.000 abstract description 2
- 239000003242 anti bacterial agent Substances 0.000 abstract 2
- 231100000331 toxic Toxicity 0.000 abstract 2
- 230000002588 toxic effect Effects 0.000 abstract 2
- 241000186046 Actinomyces Species 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 13
- 238000009472 formulation Methods 0.000 description 10
- 208000030852 Parasitic disease Diseases 0.000 description 8
- 241000243774 Trichinella Species 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 230000002141 anti-parasite Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 244000144972 livestock Species 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 241000244157 Taenia solium Species 0.000 description 4
- 241000607479 Yersinia pestis Species 0.000 description 4
- 239000003096 antiparasitic agent Substances 0.000 description 4
- 244000078703 ectoparasite Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000003071 parasitic effect Effects 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229940068968 polysorbate 80 Drugs 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000253350 Capillaria Species 0.000 description 3
- 241000242722 Cestoda Species 0.000 description 3
- 241001137876 Diphyllobothrium Species 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 241000244206 Nematoda Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 241000242678 Schistosoma Species 0.000 description 3
- 241000244174 Strongyloides Species 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 235000013330 chicken meat Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241001465677 Ancylostomatoidea Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- 241000223935 Cryptosporidium Species 0.000 description 2
- 241001060517 Dicranolaius bellulus Species 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000242711 Fasciola hepatica Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 2
- 241000257226 Muscidae Species 0.000 description 2
- 241000243981 Onchocerca Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000242541 Trematoda Species 0.000 description 2
- 241000869417 Trematodes Species 0.000 description 2
- 230000000884 anti-protozoa Effects 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 208000006275 fascioliasis Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229960003439 mebendazole Drugs 0.000 description 2
- BAXLBXFAUKGCDY-UHFFFAOYSA-N mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 description 2
- 230000001617 migratory effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 239000004540 pour-on Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000005660 Abamectin Substances 0.000 description 1
- 241000254032 Acrididae Species 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000356061 Acuaria Species 0.000 description 1
- 241001147657 Ancylostoma Species 0.000 description 1
- 241000244023 Anisakis Species 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 241001124076 Aphididae Species 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 241000244186 Ascaris Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000893172 Chabertia Species 0.000 description 1
- 241000202814 Cochliomyia hominivorax Species 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 241000935794 Dipylidium Species 0.000 description 1
- 241000243990 Dirofilaria Species 0.000 description 1
- 241000224431 Entamoeba Species 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 241000498256 Enterobius Species 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 241000258937 Hemiptera Species 0.000 description 1
- 241000920462 Heterakis Species 0.000 description 1
- 241000679711 Homona Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000243785 Meloidogyne javanica Species 0.000 description 1
- 241000243789 Metastrongyloidea Species 0.000 description 1
- 241000556230 Metastrongylus Species 0.000 description 1
- 241001137878 Moniezia Species 0.000 description 1
- 101100400378 Mus musculus Marveld2 gene Proteins 0.000 description 1
- 241001137882 Nematodirus Species 0.000 description 1
- 241000510960 Oesophagostomum Species 0.000 description 1
- 241000238814 Orthoptera Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000904715 Oxyuris Species 0.000 description 1
- 241001480233 Paragonimus Species 0.000 description 1
- 241000935974 Paralichthys dentatus Species 0.000 description 1
- 241000531596 Paramphistomum Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 241001222576 Raillietina Species 0.000 description 1
- 241000269851 Sarda sarda Species 0.000 description 1
- 235000005775 Setaria Nutrition 0.000 description 1
- 241000232088 Setaria <nematode> Species 0.000 description 1
- 241000258242 Siphonaptera Species 0.000 description 1
- 241001617580 Stephanurus Species 0.000 description 1
- 241000122932 Strongylus Species 0.000 description 1
- 241000244155 Taenia Species 0.000 description 1
- 241001454295 Tetranychidae Species 0.000 description 1
- 241000607216 Toxascaris Species 0.000 description 1
- 241000244031 Toxocara Species 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 241000243797 Trichostrongylus Species 0.000 description 1
- 241001489151 Trichuris Species 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 241000244002 Wuchereria Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000895 acaricidal effect Effects 0.000 description 1
- 239000000642 acaricide Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000013057 ectoparasiticide Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 244000000053 intestinal parasite Species 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- OPXLLQIJSORQAM-UHFFFAOYSA-N mebendazole Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1C(=O)C1=CC=CC=C1 OPXLLQIJSORQAM-UHFFFAOYSA-N 0.000 description 1
- FXWHFKOXMBTCMP-WMEDONTMSA-N milbemycin Natural products COC1C2OCC3=C/C=C/C(C)CC(=CCC4CC(CC5(O4)OC(C)C(C)C(OC(=O)C(C)CC(C)C)C5O)OC(=O)C(C=C1C)C23O)C FXWHFKOXMBTCMP-WMEDONTMSA-N 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000005645 nematicide Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、抗生物質IKD−8344物質を有効成分と
して含有することを特徴とする駆虫剤、殺虫剤及び抗原
虫剤に関するものである。更に詳細には、本発明は、人
間、動物及び植物に寄生する寄生虫(蝶虫類及び原虫類
)、外部寄生虫、昆虫及びダニに対し、有用性を有する
駆虫剤、殺虫剤及び抗原虫剤である。DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to anthelmintic agents, insecticides, and antiprotozoal agents characterized by containing the antibiotic IKD-8344 substance as an active ingredient. More specifically, the present invention provides anthelmintic agents, insecticides, and antiprotozoa having utility against parasites (sphenoid and protozoan), ectoparasites, insects, and mites that infect humans, animals, and plants. It is a drug.
駆虫・殺虫作用を有する化合物は多数知られているが、
本発すの抗生物質IKD−8344物質のような微生物
生産物質で駆虫・殺虫活性を有する物質としては、デス
トマイ/ン、ハイグロマイシン、アベルメクチン、ミル
ベマイシン等が挙げられる。Many compounds are known to have anthelmintic and insecticidal effects, but
Examples of microorganism-produced substances having anthelmintic and insecticidal activities, such as the antibiotic IKD-8344 of the present invention, include destomycin, hygromycin, avermectin, and milbemycin.
般に寄生虫症は、寄生虫、すなわち単細胞の原生動物(
原虫類)ないし多細胞の蝶虫類が動物宿主に寄生感染す
ることにより引き起こされる。In general, parasitic diseases are caused by parasites, i.e., single-celled protozoa (
It is caused by parasitic infection of an animal host by a protozoan or multicellular butterfly.
寄生虫症は、わが国では、環境衛生の改善により著明に
減少したとされるが、世界的見地から見れば、特に開発
途上国において広く蔓延し、相当な被害を与えている。Parasitic diseases are said to have decreased markedly in Japan due to improvements in environmental sanitation, but from a global perspective, they are widespread, especially in developing countries, and cause considerable damage.
最近の日本は、これら諸外国への長・短期旅行者による
感染移入やいわゆるグルメブーム(生獣・魚肉飲食)に
よる感染など、寄生虫症が新たな増加傾向を見せ始約て
いる。Recently, parasitic diseases have begun to show a new increasing trend in Japan, including infections introduced by long-term and short-term travelers to these foreign countries and infections caused by the so-called gourmet boom (eating and drinking of raw animals and fish meat).
また、寄生虫症は、豚、馬、牛、羊、山羊、犬、猫およ
び家禽等の家畜動物において普遍的かつ重大な経済的問
題である。すなわち、寄生虫の感染によって、感染動物
は貧血、栄養失調、衰弱、体重損失、腸管壁及び他の組
織、器官の重大な損傷を引き起こし、飼料効率の低下や
生産性低下の一因となっており、経済的な損失が大きい
。Parasitic diseases are also a common and serious economic problem in domestic animals such as pigs, horses, cattle, sheep, goats, dogs, cats and poultry. In other words, parasitic infections can cause infected animals to suffer from anemia, malnutrition, wasting, weight loss, and severe damage to the intestinal wall and other tissues and organs, contributing to reduced feed efficiency and productivity. This results in large economic losses.
従って、新規な駆虫剤、殺虫剤あるいは抗原虫剤を提供
することは常に求められている重要課題である。Therefore, it is always important to provide new anthelmintic agents, insecticides, or antiprotozoal agents.
本発明は、前期の問題点を解決するた杓、抗生物質IK
D−8344物質(以下車にr8344物質」と略記す
る)を含有する駆虫剤、殺虫剤及び抗原虫剤を提供する
ものである。The present invention solves the problems of the previous stage, and the antibiotic IK
The present invention provides an anthelmintic, an insecticide, and an antiprotozoal agent containing the D-8344 substance (hereinafter abbreviated as "R8344 substance").
本発明者らは、先にアルカロミセス属と命名したー放線
菌が生産する、8344物質を見いだした(特開平2−
009382)。The present inventors previously discovered 8344 substances produced by actinomycetes, which we named the genus Alcalomyces (Japanese Patent Application Laid-Open No.
009382).
8344物質は、低毒性で優れた抗腫瘍活性を有し、下
記の構造式を有する。Substance 8344 has low toxicity and excellent antitumor activity, and has the following structural formula.
Hi 「 CH。Hi " CH.
今回、新たに8344物質が、人間、動物及び植物に寄
生する寄生虫(螺虫類及び原虫類)、外部寄生虫、昆虫
及びダニに対して、内部及び外部駆虫剤、殺虫剤、抗原
虫剤として有用性を有することを見いだし、本発明を完
成するに至った。This time, 8,344 new substances have been added as internal and external anthelmintics, insecticides, and antiprotozoans against parasites (screwworms and protozoa), ectoparasites, insects, and mites that parasitize humans, animals, and plants. The present inventors have discovered that the present invention has useful properties as a method, and have completed the present invention.
8344物質を駆虫剤、殺虫剤、抗原虫剤として適用し
ようとする動物としては、豚、馬、牛、羊、山羊、兎、
鶏、アヒル、七面鳥、犬、猫、小鳥、猿、二十日ネズミ
、黒ネズミ、モルモフト等の家畜、家禽、ペット、実験
動物を挙げることができる。Animals to which the 8344 substance is applied as anthelmintic, insecticide, and antiprotozoal agent include pigs, horses, cows, sheep, goats, rabbits,
Examples include livestock, poultry, pets, and laboratory animals such as chickens, ducks, turkeys, dogs, cats, small birds, monkeys, 20-day rats, black rats, and guinea pigs.
これらの動物の寄生虫では、螺虫類に属する線虫類が、
各種の動物に深刻な感染を引き起こす。Among the parasites of these animals, nematodes belonging to the class Scrophida are
Causes serious infections in various animals.
その−船釣な種類は、畑土(Ascaris)、犬姻虫
(Toxocara)、犬小蛎虫(Toxascari
s)、馬蛎虫(Para、5caris)、鶏蛎虫(八
5caridia) 、鶏盲腸虫(Heterakis
) 、p虫(Oxyuris) 、桿虫(Strong
yIoicles) 、郷土(Trichuris)
、毛細線虫(Capillaria)、旋毛上(Tri
chinella) 、円虫(Strongylus。The types of boat fishing are Ascaris, Toxocara, and Toxascari.
s), Para, 5 caris, Chicken caedia (Para, 5 caris), Chicken caecum (Heterakis).
), Oxyuris, Strong
yIoicles), native land (Trichuris)
, Capillaria, Tri
chinella), Strongylus.
Trioclontophorus)、毛線虫(Tri
chonema)、豚腎上(Stephanurus)
、腸結節虫(Oesophagostomum)、大
口腸線虫(Chabertia> 、開嘴虫(Syng
amus)、鉤虫(Ancylostoma、 IJn
cinaria 、 NecatorXBunost。Trioclontophorus), Hairy nematode (Tri
chonema), pig kidney (Stephanurus)
, Oesophagostomum, Chabertia, Syn
amus), hookworm (Ancylostoma, IJn)
cinaria, NecatorXBunost.
mum)、毛様線虫(Trichostrongylu
s)、クーパー毛様線虫(Cooper i a)、綿
類毛様線虫(Nematodirus)、捻転胃虫(H
aemonchus)、オステルターグ胃虫(口ste
rtagia)、肺虫(Dictyocau)us。mum), Trichostrongylu
s), Cooper ia, Nematodirus, H
aemonchus), Ostertag stomach worm (stomach worm)
rtagia), Lungworm (Dictyocau) us.
Metastrongylus) 、太糸条虫(Dir
ofilaria) 、多孔頭糸条虫(Parafil
ar+a) 、馬糸条虫(Setaria)、オンコセ
ル力(Onchocerca)、胃虫(Habrone
ma。Metastrongylus), Dir.
ofilaria), Parafila
ar+a), Setaria, Onchocerca, Habrone
ma.
Arduenna、 Acuaria)である。また、
条虫類として、裂頭条虫(Diphyllobothr
ium)、アノブロセハラ属(Anoplocepha
ra) 、モニイジア属(t、1oniezia)、犬
条虫(Dipylidium)、無鉤条虫及び有鉤条虫
(Taenia) 、嚢虫(Dithyridium)
、レーリチナ属(Raillietina) 、色土
(巳ch i nococcus)等が、吸虫類として
は、住血吸虫(Schistosoma) 、双口吸虫
(Paramphistomum)、肝蛭(Fasci
ola)、その他種々の寄生虫が知られている。Arduenna, Acuaria). Also,
As a tapeworm, Diphyllobothr
ium), Anoplocepha spp.
ra), Moniezia (T, 1oniezia), Dipylidium, Taenia solium and Taenia, Dithyridium
, the genus Raillietina, and the chinococcus, and the trematodes include Schistosoma, Paramphistomum, and Fasci flukes.
ola) and various other parasites are known.
また、8344物質は、人間に感染する寄生虫に対して
も有用である。人間の消化管に寄生する一般的な寄生虫
としては、組上(^5caris) 、鉤虫(Ancy
lostomaSNecator)、糞線虫(Stro
ngyloides)、旋毛虫(Trichinell
a) 、毛細線虫(Capillaria)、郷土(T
richuris) 、蜆虫(Enterobius)
、アニサキス(Anisakis)、フィリピン毛頭虫
(Capillaria)である。血管系あるいは胃腸
以外の他の組織、器官に寄生する医学的に重要な寄生虫
はフィラリγ科の寄生虫、例えば、バンクロフト糸条虫
(Wuchereria)、マレー糸条虫(Brugi
a)、オンコセル力(Onchocerca)、ロア糸
条虫(Loa) 、メディナ虫(Dracunculu
s)及び腸寄生虫である糞線虫及び旋毛虫の腸外寄生段
階のもの、皮下に寄生する顎口虫(Gnathosto
ma)である。また、動物から人間に感染する太糸条虫
(Dirofilaria)、犬蛎虫(Toxocar
a)が知られている。Substance 8344 is also useful against parasites that infect humans. Common parasites that infect the human gastrointestinal tract include ``caris'' and hookworm.
lostomaSNecator), Strongyloides nematodes (Stro
ngyloides), Trichinella
a), Capillaria, local (T.
richuris), Enterobius
, Anisakis, and Capillaria. Medically important parasites that parasitize the vascular system or other tissues and organs other than the gastrointestinal tract include parasites of the Filaridae family, such as Wuchereria and Brugi.
a), Onchocerca, Loa, Dracuncula
s) and the extraintestinal parasitic stages of the intestinal parasites Strongyloides and Trichinella, as well as the subcutaneous parasitic gnathostomes.
ma). In addition, Dirofilaria and Toxocar, which can be transmitted from animals to humans.
a) is known.
また、条虫類としては、広範装幀条虫及びマンソン装幀
条虫(Diphyllobothrium)、無鉤条虫
及び有鉤条虫(Taenia)、色土(已ch i n
ococcus)、有鉤嚢虫((1’ysticerc
us) 、小型条虫類が、吸虫類とじては、住血吸虫(
Schistosoma)、肝吸虫(fl’1onor
chis)、肺吸虫(Paragonimus) 、肝
蛭(Fasciola)等が知られている。In addition, tapeworms include Diphyllobothrium, Diphyllobothrium, Taenia solium, Taenia solium, and Taenia solium.
ococcus), Taenic cyst ((1'ysticerc)
us), small tapeworms, but trematodes include schistosomes (
Schistosoma), liver fluke (fl'1onor
chis), lung fluke (Paragonimus), liver fluke (Fasciola), etc.
寄生虫症を引き起こす原虫類としては、マラリア原虫(
Plasmodium) 、リーシュ?−’−ア(Le
i−shmania)、トリパノソ−7(Trypan
osoma)、赤痢アメーバ(Entamoeba)、
鞭毛虫(Giardia)、トリコモナス(Tr ic
homonas)、トキソプラズマ(Tox。The protozoa that cause parasitic diseases include malaria parasites (
Plasmodium), leash? -'-A (Le
i-shmania), trypanoso-7 (Trypan
osoma), Entamoeba histolytica (Entamoeba),
Flagellates (Giardia), Trichomonas (Tric)
homonas), Toxoplasma gondii (Tox.
plasma) 、クリプトスポリジウム(Crypt
ospor idium) 、コクシジウム(εime
ria)、ニューモシスチス(Pneumocysti
s)等が挙げられる。plasma), Cryptosporidium (Crypt
ospor idium), coccidium (εime
ria), Pneumocystis
s) etc.
動物、人間に感染する外部寄生虫の例は、咬刺昆虫、吸
血昆虫、ノミ、シラミ、イエバエ、コダニ、マダニ及び
他の移動性双翅類の幼虫のような節足性外寄生生物であ
る。Examples of ectoparasites that infect animals, humans are arthropod ectoparasites such as biting insects, blood-sucking insects, fleas, lice, house flies, spider mites, ticks and other migratory dipteran larvae.
家庭の害虫としては、ゴキブリ、衣蛾、かつおぶしむし
及びイエバエが挙げられる。Household pests include cockroaches, cloth moths, bonito bugs, and houseflies.
また、貯蔵穀物の害虫、例えば、コクヌストモドキ、コ
メノゴミムシダマシ、農作物の害虫、例えば、はだに、
あぶらむし、移動性の直翅目、例えば、バッタ、及び植
物組織中に住む昆虫の幼虫が挙げられる。さらに、土壌
線虫及び根瘤線虫のような植物寄生虫が挙げられる。In addition, pests of stored grains, such as rice beetles, rice beetles, and pests of agricultural crops, such as barley beetles,
Included are aphids, migratory Orthoptera, such as grasshoppers, and the larvae of insects that live in plant tissues. Further examples include plant parasites such as soil nematodes and root-knot nematodes.
8344物質は、動物または人の医薬として、寄生虫症
の治療または予防の目的で、いずれかの在来の方法で投
与することができる。投与方法は、経口的、非経口的の
いずれも可能であり、経口投与する場合は、軟・硬カプ
セル剤または錠剤、丸剤、粉剤、顆粒剤、細粒剤、散剤
、シロップ、腸溶剤、懸濁剤、ペーストとして、また、
動物用の液体飲料や飼料中に配合することにより、投与
することができる。非経口投与する場合は、注射剤、点
滴剤、止剤、乳剤、懸濁剤、滴下剤(例えば、点眼剤、
点鼻剤)として、また軟膏剤、クリーム剤、液剤、ロー
ション剤、スプレー剤、エアゾル剤、パップ剤、テープ
剤として、粘膜または経皮吸収が維持できるような剤型
で投与され得る。また、家畜用の乳腺内装剤及びポアー
オン(Pour−on)として投与され得る。The 8344 substance can be administered in any conventional manner for the treatment or prevention of parasitic diseases as an animal or human medicine. The administration method can be either oral or parenteral, and when administered orally, soft/hard capsules or tablets, pills, powders, granules, fine granules, powders, syrups, enteric coated agents, As a suspension, paste, and
It can be administered by incorporating it into liquid drinks or feed for animals. For parenteral administration, injections, drops, fixatives, emulsions, suspensions, drops (e.g. eye drops,
It can be administered in a dosage form that maintains mucosal or transdermal absorption, such as as a nasal spray), ointment, cream, liquid, lotion, spray, aerosol, poultice, or tape. It can also be administered as a mammary gland preparation and pour-on for livestock.
8344物質を製剤化するに当たっては、医薬的に許容
し得る可溶化剤、懸濁剤、乳化剤、分散剤、界面活性剤
、結合剤、濃化剤、充填剤、賦形剤、滑沢剤、崩壊剤、
湿潤剤、佐剤及びその他を用いて固体、半固体、液体等
での製剤の製造に適するように、適宜行うことができる
。さらに、安定化剤、着色剤及び香料を使用してもよい
。活性成分は、製剤中に疾病の治療または予防に十分な
里で含有されている。In formulating the 8344 substance, pharmaceutically acceptable solubilizing agents, suspending agents, emulsifying agents, dispersing agents, surfactants, binders, thickening agents, fillers, excipients, lubricants, disintegrant,
Wetting agents, adjuvants and others may be used as appropriate to suit the preparation of solid, semi-solid, liquid, etc. formulations. Additionally, stabilizers, colorants and fragrances may be used. The active ingredient is contained in the formulation in sufficient quantity to treat or prevent the disease.
8344物質を動物または人の医薬として使用する場合
、用いられる8344物質の最適の量は、治療または予
防の別、感染動物の種類、感染の型及び程度、剤型等に
よって左右されるが、一般に、経口投与の場合、1日当
り、約0.001ないし50mg/kg体重の範囲で、
その上限は好ましくは約25mg/kg体重程度であり
、非経口投与の場合、その上限は約5mg/kg体重程
度であり、好ましくは約1mg/kg体重程度であり、
単回あるいは分割して1ないし5日間程度投与され得る
。When using 8344 substance as a medicine for animals or humans, the optimal amount of 8344 substance to be used depends on whether the treatment is for treatment or prevention, the type of infected animal, the type and degree of infection, the dosage form, etc. , in the range of about 0.001 to 50 mg/kg body weight per day for oral administration,
The upper limit is preferably about 25 mg/kg body weight, and in the case of parenteral administration, the upper limit is about 5 mg/kg body weight, preferably about 1 mg/kg body weight,
It can be administered once or in divided doses for about 1 to 5 days.
外部寄生虫駆除用、殺虫剤用及び農業有害生物処理用等
園芸または農業用には、8344物質は、標準的な1芸
または農業上の方法に従って、噴霧剤、粉末、ペレット
、エマルジョン及びこれらに類するものとして適用され
る。また、他の殺虫剤、殺ダニ剤及び殺線虫剤と混合し
て処方することもできる。For horticultural or agricultural purposes, such as ectoparasiticides, insecticides, and agricultural pest treatments, 8344 substances can be used in sprays, powders, pellets, emulsions, and the like according to standard industrial or agricultural methods. shall be applied as similar. It can also be formulated by mixing with other insecticides, acaricides, and nematicides.
処方において、8344物質の濃度は、一般に0.01
〜99重量%、好ましくは0.01〜10重量%程度で
ある。商業的製品は、一般に、例えば使用に際して適当
な濃度に稀釈して使用する濃厚な組成物として提供され
る。In the formulation, the concentration of the 8344 substance is generally 0.01
It is about 99% by weight, preferably about 0.01 to 10% by weight. Commercial products are generally provided, for example, as concentrated compositions that are diluted to the appropriate concentration for use.
〔8344物質の急性毒性〕
BDF、マウスに腹腔的投与で、5mg/kg単回投与
、又は2mg/kg1日1回連日5日間投与しても死亡
例は観察されなかった。[Acute Toxicity of Substance 8344] No deaths were observed when BDF was administered intraperitoneally to mice at a single dose of 5 mg/kg or once a day for 5 days.
また、d、 d r雄性マウスに経口投与で25mg/
kg単回投与で毒性及び死亡例は観察されなかった。In addition, 25 mg/d was administered orally to male mice.
No toxicity or mortality was observed after a single administration of 1 kg.
以下の製剤例及び試験例は単に本発明の例示目的に提供
され、その範囲を限定するものではない。The following formulation examples and test examples are provided merely for the purpose of illustrating the present invention and are not intended to limit its scope.
製剤例1 (錠剤)
[A]
8344物質 2.00 g乳
糖 17.94gヒドロ
キシプロピルセルロース 0.06 gステアリン酸
マグネシウム 0.20 g〔B〕
酢酸フタル酸セルロース 0.60 g[A]
の成分をとり、よく混合し、これを直接加圧するか、ま
たはよく練合した後、押し出し型製粒機のスクリーンを
通して顆粒成形を行い、十分乾燥後、加圧して錠剤10
0個を調製した。Formulation example 1 (tablet) [A] 8344 substances 2.00 g milk
Sugar 17.94 g Hydroxypropyl cellulose 0.06 g Magnesium stearate 0.20 g [B] Cellulose acetate phthalate 0.60 g [A]
Take the ingredients, mix them well, press them directly, or knead them well, then form them into granules through the screen of an extrusion type granulator, and after sufficient drying, press them to make tablets 10
0 pieces were prepared.
更に、必要に応じて成形した錠剤をよく溶解した〔B〕
の基剤を被覆して腸溶性錠剤とする。Furthermore, if necessary, the molded tablets were well dissolved [B]
Enteric-coated tablets are prepared by coating the base material.
製剤例2 (カプセル剤)
〔A〕
8344物質 2.00 g乳
糖 10.46gヒド
ロキシプロピルセルロース 0.04 g[B]
酢酸フタル酸セルロース 1.00 g上記の
〔ハ〕の成分をとり、よく混合した後、常法に従って粒
状に成形し、これをよく乾燥して篩別し、カプセル用に
適した顆粒剤とし、これをカプセルに充填してカプセル
剤100個を調製した。Formulation example 2 (capsule) [A] 8344 substances 2.00 g milk
Sugar 10.46 g Hydroxypropyl cellulose 0.04 g [B] Cellulose acetate phthalate 1.00 g After taking the ingredients in [C] above and mixing them well, form them into granules according to a conventional method, and dry them thoroughly. The mixture was sieved to obtain granules suitable for capsules, and the granules were filled into capsules to prepare 100 capsules.
更に必要に応じ、この顆粒剤を浮遊流動させながら溶解
した〔B〕の基剤を被覆し、腸溶性の顆粒剤として、こ
れをカプセルに充填して腸溶性カプセル剤とする。Further, if necessary, the granules are coated with the dissolved base [B] while floating and flowing to form enteric-coated granules, which are then filled into capsules to obtain enteric-coated capsules.
製剤例3 (注射剤)
83471物質
ベンジルアルコール
ポリソルベート80
プロピレングリコール
注射用蒸留水
0、50 g
2、00 g
10、00 g
50、00 g
適量
全量 100m1
8344物質を、ベンジルアルコール、ポリソルベート
80及びプロピレングリコールに溶解し、注射用蒸留水
を加えて、全量を100mfとする。Formulation example 3 (injection) 83471 substance benzyl alcohol polysorbate 80 propylene glycol Distilled water for injection 0,50 g 2,00 g 10,00 g 50,00 g Appropriate total amount 100 ml Substance 8344, benzyl alcohol, polysorbate 80 and propylene glycol and add distilled water for injection to bring the total volume to 100 mf.
無菌的に製造し、無菌的に分注する。Manufactured aseptically and dispensed aseptically.
製剤例4 (家畜用乳腺内注射液)
8344物質 0.10 g落花生
油 1.82 g白蜜鑞
0.12 gポリソルベート8
0 0.06 g8344物質以外の成分
を160℃で加熱撹拌し、冷却後、8344物質を加え
て、分散させる。Formulation example 4 (intramammary injection for livestock) 8344 substances 0.10 g Peanut oil 1.82 g White honey wax
0.12 g polysorbate 8
0 0.06 gThe components other than substance 8344 are heated and stirred at 160°C, and after cooling, substance 8344 is added and dispersed.
製剤例5 (家畜用経口水薬)
8344物質 0.50 gベンジ
ルアルコール 2. OOgポリソルベー
ト80 5.00 gプロピレングリコ
ール 30. OOg水
適量全量 100d
8344物質を、ベンジルアルコール、ポリソルベート
80及びプロピレングリコールに溶解し、水を加えて全
量を100m1とする。必要に応じて、燐酸緩衝液を加
えて、p++を中性付近に調整する。Formulation Example 5 (Oral liquid medicine for livestock) 8344 substances 0.50 g Benzyl alcohol 2. OOg Polysorbate 80 5.00 g Propylene Glycol 30. OOg water
Appropriate amount Total amount 100d Dissolve substance 8344 in benzyl alcohol, polysorbate 80 and propylene glycol, and add water to make the total amount 100ml. If necessary, add phosphate buffer to adjust p++ to near neutrality.
製剤例6 (家畜用ポアーオン)
8344物質 1.00gジメチル
スルホキシド 10.00 gメチルイソブチ
ルケトン 30. OOgプロピレングリコール
適量全量 10〇−
8344物質をジメチルスルホキシド及びメチルイソブ
チルケトンに溶解し、プロピレングリコールを加えて全
量を100−とする。必要に応じて顔料を加える。Formulation Example 6 (Pour-on for livestock) 8344 substances 1.00 g dimethyl sulfoxide 10.00 g methyl isobutyl ketone 30. OOg Propylene glycol appropriate amount total amount 100- Dissolve the 8344 substance in dimethyl sulfoxide and methyl isobutyl ketone and add propylene glycol to make the total amount 100-. Add pigment if necessary.
試験例1 in vitro抗寄生虫(殺虫)試験1
)供試主神
旋毛土類のTrichinella 5piralis
(Thai 5train)ならびにT、 pseud
ospiralisの成熟幼虫。Test Example 1 In vitro antiparasitic (insecticidal) test 1
) Trichinella 5piralis
(Thai 5train) and T, pseudo
Mature larva of P. ospiralis.
2)試験方法
DMSOにて溶解した8344物質を、M199培地(
20%牛脂児血清及びカナマイシンを含む)で2段階希
釈して、96穴平底マイクロプレートの各3穴に分注し
1、上記幼虫を数10隻ずつ投入し、直ちに37℃15
%CO2で培養した。2) Test method Substance 8344 dissolved in DMSO was added to M199 medium (
(containing 20% tallow serum and kanamycin), aliquoted into 3 wells each of a 96-well flat-bottomed microplate, put several tens of the above larvae in each, and immediately incubate at 37°C at 15°C.
% CO2.
対照は、M199単味ならびに溶解に用いた含量%のD
MSOを含むM199による。The controls were M199 alone and the content of % D used for dissolution.
By M199 including MSO.
また、既知の抗寄生虫物質であるMebendazol
eについても上記に準じた方法で検討して本物質と比較
した。Also, Mebendazol, a known antiparasitic substance
e was also investigated using a method similar to the above and compared with this substance.
3)判定基準
培養開始後、経口的に虫体の生死または死滅状態を観察
し、死亡率及びED、。値を算定した。3) Judgment Criteria After the start of culture, the viability or deadness of the worms was observed orally, and the mortality rate and ED. The value was calculated.
4)試験結果
■8344物質: Trichinella 5pir
alis及びT、pseudosp+ral+s
死亡率%(培養3日目)
■Mebendazole:Trichinella
5piral+s死亡率%(培養3.5日目)
本ある被検群の全個体が完全に生存または死滅している
ことを判定することは困難であり、計算の便宜上100
%は99%、0%は1%とした。4) Test results ■8344 substance: Trichinella 5pir
alis and T, pseudosp+ral+s Mortality rate % (3rd day of culture) ■Mebendazole: Trichinella
5piral + s mortality rate% (3.5 days of culture) It is difficult to determine whether all individuals in a certain test group are completely alive or dead, so for convenience of calculation, 100%
% was 99% and 0% was 1%.
8344物質の抗寄生虫(殺虫)作用は比較的即効的と
思われ、培養3日目までに全体の動向が明らかとなって
いる。高濃度域では、虫体を曝露してから半日強でその
活動性に影響がみられて、コイル状に静止しがちな個体
が出現し、経口的に活動の停止するものが増えた。The antiparasitic (insecticidal) effect of Substance 8344 appears to be relatively immediate, and the overall trend becomes clear by the third day of culture. In the high concentration range, the activity of the insects was affected a little more than half a day after exposure, with some individuals tending to stay still in a coiled state, and an increasing number of insects becoming inactive after oral administration.
EDso値は、T、 5piralisに対しては、1
.65μs/mj2、T、 pseudospiral
isに対しては、2.18μg/m1と算定された。The EDso value is T, 1 for 5piralis
.. 65μs/mj2, T, pseudospiral
For is, it was calculated to be 2.18 μg/ml.
一方、比較対照薬として用いたMebendazole
はかなり遅効性であり、明らかな抗寄生虫効果は培養4
〜5日目に至ってから認められた。その作用も生体をコ
イル状に静止させることが少なかった。On the other hand, Mebendazole was used as a comparative drug.
is quite slow-acting, and the obvious antiparasitic effect is observed in culture 4
It was recognized after ~5 days. Its action also rarely caused the living body to stay still in a coiled state.
試験例2 inシ1シO抗寄生虫(駆虫)試験l)供
試主神
Trichinella 5piralis(Thai
5train)成熟幼虫。Test Example 2 In Shi 1 O Anti-parasitic (Anthelmintic) Test l) Test Main Trichinella 5piralis (Thai
5train) mature larva.
2)試験方法
ddy 7ウス(SPF雌)にT、5piralisの
幼虫を400隻/頭で感染し、感染後3日及び155日
目腸管寄生相:成主の他新生幼虫や筋肉移行期の幼虫も
対象となる)と2ケ月目(、筋肉寄生相゛成熟幼虫)に
、83/14物質を5 mg / kg体体重下でCM
C・生理食塩水PQにて経口投与した。投与約1ケ月後
、マウスを麻酔列させ、全骨格筋から人工消化法にて全
幼虫を回収して算定、それぞれの感染度・生存上数の比
較から駆虫効果を判定した。2) Test method ddy 7 mice (SPF female) are infected with 400 T.5 piralis larvae/head, and 3 and 155 days after infection Intestinal parasitic phase: In addition to adults, newborn larvae and larvae in the muscle transition stage CM 83/14 substance at 5 mg/kg of body weight at 2 months (muscle parasitic phase, mature larva)
C. Orally administered in physiological saline PQ. Approximately one month after administration, the mice were anesthetized, and all larvae were collected from all skeletal muscles by artificial digestion, and the anthelmintic effect was determined by comparing the degree of infection and the number of survivors.
試験結果 に対する毒性が低いので、 ることができる。Test results Because of its low toxicity, can be done.
有効量を安全に使用す
8344物質は、感染3日目、15日目及び2ヶ月目の
いずれの時期においても、単回投与で優れた抗寄生虫(
駆虫)活性を示した。実験に用いた旋毛上は、豚、ネズ
ミ、犬などの動物に寄生する他、人にも寄生する入獄共
通の寄生虫であり、8344物質が殺虫・駆虫活性を示
したことから、8344物質の広範囲な応用が考えられ
る。When used safely in effective doses, substance 8344 has excellent anti-parasitic properties (
showed anthelmintic) activity. The trichinella used in the experiment is a common prison parasite that infects animals such as pigs, rats, and dogs, as well as humans, and the 8344 substance showed insecticidal and anthelmintic activity. A wide range of applications are possible.
Claims (3)
含有することを特徴とする駆虫剤。(1) An anthelmintic agent characterized by containing the antibiotic IKD-8344 substance as an active ingredient.
含有することを特徴とする殺虫剤。(2) An insecticide characterized by containing the antibiotic IKD-8344 substance as an active ingredient.
含有することを特徴とする抗原虫剤。(3) An antiprotozoal agent containing the antibiotic IKD-8344 substance as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2206479A JPH0491024A (en) | 1990-08-03 | 1990-08-03 | Anthelminthic, insecticide and antiprotozoal |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2206479A JPH0491024A (en) | 1990-08-03 | 1990-08-03 | Anthelminthic, insecticide and antiprotozoal |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH0491024A true JPH0491024A (en) | 1992-03-24 |
Family
ID=16524057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2206479A Pending JPH0491024A (en) | 1990-08-03 | 1990-08-03 | Anthelminthic, insecticide and antiprotozoal |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0491024A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019064973A (en) * | 2017-10-03 | 2019-04-25 | 学校法人 愛知医科大学 | No production inhibitor and metastasis/invasion inhibitor for solid tumor |
-
1990
- 1990-08-03 JP JP2206479A patent/JPH0491024A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019064973A (en) * | 2017-10-03 | 2019-04-25 | 学校法人 愛知医科大学 | No production inhibitor and metastasis/invasion inhibitor for solid tumor |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220039429A1 (en) | Supplemented fish feed | |
Miller et al. | Larvicidal activity of Merck MK-933, an avermectin, against the horn fly, stable fly, face fly, and house fly | |
TWI342875B (en) | Novel amidoacetonitrile compounds, processes for the preparation of the compounds, compositions comprising the compounds and use of the compounds | |
JP2007516285A (en) | Animal products containing non-animal products | |
ES2365993T3 (en) | PESTICID FORMULATIONS. | |
US7396820B2 (en) | Anthelmintic formulations | |
TW200423871A (en) | Topical parasiticide formulations and methods of treatment | |
TW200932228A (en) | New use | |
ES2290000T3 (en) | ANTIHELMINTIC COMPOSITIONS CONTAINING COMBINATIONS OF AVERMECTINES OR MILBEMICINES WITH BIS-ARILIC COMPOUNDS. | |
JP4404484B2 (en) | Ectoparasites | |
RU2241331C2 (en) | Composition of enantiomers of 5-amino-3-cyano-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-trifluoromethylsulfinylpyrazole | |
US7754696B2 (en) | Application of water and organic solvent soluble Ivermectin for topical and oral use | |
US20050203034A1 (en) | Multi-action anthelmintic formulations | |
US6627613B2 (en) | Application of water and organic solvent soluble ivermectin for topical and oral use | |
EP0549441B1 (en) | Juvenile hormone agents for systemically treating ectoparasites | |
JPH0491024A (en) | Anthelminthic, insecticide and antiprotozoal | |
EP0871361B1 (en) | Agent for combating parasites in farmed fish | |
KR101357478B1 (en) | Ectoparasiticidal methods and formulations | |
JP3502103B2 (en) | Nodulisporic acid derivatives | |
JPS6018643B2 (en) | Veterinary drug composition | |
WO2005016356A1 (en) | Improved anthelmintic formulations | |
JPH1143408A (en) | Insect pest controlling agent composition | |
JP4198230B2 (en) | Method and control agent for parasites and aquatic fungus parasitic on aquatic products | |
EP1204413A2 (en) | Control of crustacean infestation of aquatic animals | |
JP3506511B2 (en) | Anthelmintic |